scholarly journals Model‐based approach for methoxy polyethylene glycol‐epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease

2020 ◽  
Vol 86 (4) ◽  
pp. 801-811
Author(s):  
Pascal Chanu ◽  
Franz Schaefer ◽  
Bradley A. Warady ◽  
Claus Peter Schmitt ◽  
Bruno Reigner ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Polyethylene Glycol ◽  
Kidney Disease ◽  
Drug Development ◽  
Model Based ◽  
Epoetin Beta ◽  
Paediatric Patients ◽  
Methoxy Polyethylene Glycol

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)

The Lancet ◽  
2007 ◽  
Vol 370 (9596) ◽  
pp. 1415-1421 ◽  
Author(s):  
Nathan W Levin ◽  
Steven Fishbane ◽  
Francisco Valdés Cañedo ◽  
Steven Zeig ◽  
George M Nassar ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Polyethylene Glycol ◽  
Kidney Disease ◽  
Epoetin Beta ◽  
Methoxy Polyethylene Glycol

scholarly journals COST-MINIMIZATION ANALYSIS OF USING SHORT AND LONG-ACTING ERYTHROPOESIS-STIMULATING AGENTS FOR CORRECTION OF NEPHROGENIC ANEMIA AGAINST THE BACKGROUND OF SUBSTITUTION THERAPY

2021 ◽  
Vol 9 (5) ◽  
pp. 387-399
Author(s):  
I. S. Krysanov ◽  
E. Yu. Ermakova ◽  
L. B. Vaskova ◽  
M. V. Tiapkina
Keyword(s):  
Chronic Kidney Disease ◽  
Polyethylene Glycol ◽  
Drug Therapy ◽  
Kidney Disease ◽  
Darbepoetin Alfa ◽  
Weekly Dose ◽  
Epoetin Alfa ◽  
Epoetin Beta ◽  
Long Acting ◽  
Methoxy Polyethylene Glycol

Clinical trials conducted in various countries indicate that the use of epoetin alfa in patients with nephrogenic anemia in chronic kidney disease can increase the effectiveness of treatment, reduce the incidence of cardiovascular and infectious complications, and reduce mortality in patients with chronic kidney disease.The aim of the article was to conduct a comparative clinical and economic assessment of the treatment costs of nephrogenic anemia in adult dialysis patients with recombinant human erythropoietins: epoetin alfa, darbepoetin and long-acting methoxy polyethylene glycol – epoetin beta.Materials and methods. The study took into account direct medical costs of nephrogenic anemia pharmacotherapy on the basis of 1 year maintenance therapy according to the following scheme: epoetin alfa – 3 times per week, darbepoetin alfa – once per week, methoxy polyethylene glycol – epoetin beta – once per 2 or 4 weeks. A “costs minimization” analysis was performed for equivalent maintenance epoetins doses for intravenous and subcutaneous administrations. Epoetin alpha equivalents were calculated for an average patient weighing 75 kg by converting a weekly dose of short-acting epoetin (7500 IU) into equivalent doses using dose conversion factors.Results. In the hypothetical cohort of patients under study, epoetin alfa, darbepoetin alfa, and methoxy polyethylene glycol – epoetin beta not differ in effectiveness in achieving target Hb values and in safety. With the equal effectiveness of the investigated drugs, in the studied patients, intravenous epoetin alfa can be less expensive drug therapy relative to the equivalent doses obtained by the calculation: darbepoetin by 14–24% and methoxy polyethylene glycol – epoetin beta by 4–30%. The change-over of patients to the subcutaneous administration makes it possible to decline a weekly dose of epoetin alfa by 20–30% by reducing the frequency of taking the drug to twice a week, and to reduce the cost of drug therapy by a third.Conclusion. Intravenous and subcutaneous administrations of epoetin alfa 2500 IU may be a more economical drug therapy in comparison with the equivalent doses of darbepoetin and methoxy polyethylene glycol – epoetin beta.

Treatment of Anemia Associated with Chronic Kidney Disease with Methoxy Polyethylene Glycol-Epoetin Beta

2009 ◽  
Vol 1 ◽  
pp. CMT.S3339
Author(s):  
Tejas Patel ◽  
Ajay K. Singh
Keyword(s):  
Chronic Kidney Disease ◽  
Polyethylene Glycol ◽  
Kidney Disease ◽  
The United States ◽  
Erythropoietin Receptor ◽  
Target Range ◽  
Recombinant Erythropoietin ◽  
The European Union ◽  
Epoetin Beta ◽  
Methoxy Polyethylene Glycol

Anemia resulting from a relative deficiency of erythropoietin commonly complicates chronic kidney disease (CKD). With the introduction of recombinant erythropoietin two decades ago, there has been a dramatic reduction in the need for blood transfusions in CKD patients. Epoetin alpha is a first generation erythropoiesis stimulating agent (ESA) that needs to be administered frequently because of its short half-life. Methoxy ethylene glycol-epoetin beta is a longer acting ESA that acts as a continuous erythropoietin receptor activator and is given once every 2 to 4 weeks. In short term clinical studies, Methoxy polyethylene glycol-epoetin beta has been observed to be comparable with other ESAs with regard to safety and efficacy in maintaining hemoglobin levels in the target range. However, hemoglobin is no longer a clinically valid surrogate for safety i.e. correction of anemia does not translate into better clinical outcome. Long term studies evaluating hard end-points such as death and cardiovascular events are lacking. Methoxy polyethylene glycol-epoetin beta has been approved for use in the European Union since 2007 while its use in the United States is prohibited on legal grounds.

Impact of anemia treatment with methoxy polyethylene glycol-epoetin beta on polymorphonuclear cells apoptosis in predialysis patients with chronic kidney disease

2015 ◽  
Vol 67 (5) ◽  
pp. 842-845 ◽  
Author(s):  
Piotr Bartnicki ◽  
Ewa Majewska ◽  
Mariusz Kowalczyk ◽  
Zbigniew Baj ◽  
Maciej Banach ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Polyethylene Glycol ◽  
Kidney Disease ◽  
Polymorphonuclear Cells ◽  
Epoetin Beta ◽  
Methoxy Polyethylene Glycol ◽  
Anemia Treatment

scholarly journals Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease

2012 ◽  
pp. 53 ◽  
Author(s):  
Naro Ohashi ◽  
Sakao ◽  
Yasuda ◽  
Kato ◽  
Fujigaki
Keyword(s):  
Chronic Kidney Disease ◽  
Polyethylene Glycol ◽  
Kidney Disease ◽  
Epoetin Beta ◽  
Methoxy Polyethylene Glycol
Sign in / Sign up

Export Citation Format

Share Document